SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Nuveen Churchill Direct Lending Corp. disclosed its Q2 2026 financial results for the quarter ended June 30, 2026, reporting net investment income of $0.41 per share, net realized and unrealized losses, and NAV per share of $17.19. The earnings release was issued on August 6, 2026 and included consolidated financial statements and operational highlights.
View raw filing on EDGAR →BlackSky issued a press release on August 6, 2026 announcing its financial results for the second quarter ended June 30, 2026, disclosing total revenue of $33.3 million (up 50% YoY), record space-based intelligence revenue of $25 million, net loss of $20.8 million, and Adjusted EBITDA of $4.7 million. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings disclosures.
View raw filing on EDGAR →Vivani Medical announced successful completion of enrollment and dosing of all 20 participants in the SLIM-1 Phase 1 clinical trial for NPM-139, a semaglutide implant candidate. This is a material clinical development milestone—full enrollment ahead of schedule and successful dosing of all participants—that advances the company's product pipeline and supports the anticipated Phase 2 initiation in 2027. While not a specific named event type, this is clearly an operational/strategic milestone in drug development that would affect a reasonable investor's assessment of the company's progress and prospects.
View raw filing on EDGAR →This is a straightforward earnings release disclosing Curaleaf's Q2 2026 financial results, including net revenue of $340.1 million (10% YoY growth), gross profit margin of 50%, net income of $12.5 million, and adjusted EBITDA of $70.1 million. The press release was issued on August 5, 2026, and is attached as Exhibit 99.1 to the 8-K filing, which is the standard format for Item 2.02 earnings disclosures. The results are material to investors assessing the company's operational performance and financial condition.
View raw filing on EDGAR →Curaleaf's voluntary transition from foreign private issuer to U.S. domestic issuer status is a material governance and regulatory event. The disclosure states the Company "will voluntarily comply with the registration and ongoing reporting requirements applicable to a U.S. domestic issuer under U.S. securities laws, rather than those applicable to foreign private issuers," which represents a fundamental change in the Company's regulatory and reporting framework. This redomicile-related transition affects the Company's governance profile, compliance obligations, and investor base, and would materially affect a reasonable investor's assessment of the registrant's regulatory status and future obligations.
View raw filing on EDGAR →This is a clear earnings release disclosing Karat Packaging's Q2 2026 financial results, including record quarterly net sales of $136.3 million (up 9.9%), net income of $29.6 million (up 168.3%), and forward guidance for Q3 and full-year 2026. The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures.
View raw filing on EDGAR →This is a clear earnings release disclosing Privia Health's Q2 2026 financial results, including net income of $9.0M (+236.7% YoY), adjusted EBITDA of $37.4M (+29.1% YoY), and updated full-year 2026 guidance raised across all key metrics. The press release is attached as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures.
View raw filing on EDGAR →Immunovant issued a press release on August 6, 2026 announcing financial results for its fiscal first quarter ended June 30, 2026, including condensed consolidated statements of operations and balance sheets. The disclosure reports net loss of $153.2 million, R&D expenses of $142.6 million, cash position of $797.8 million, and clinical development updates for IMVT-1402 across six indications. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02.
View raw filing on EDGAR →The filing discloses a quarterly cash dividend of $0.49 per share of common stock declared by Kodiak Gas Services' board of directors, payable on August 27, 2026 to stockholders of record as of August 17, 2026. This is a routine but material dividend distribution to shareholders, consistent with the dividend_distribution event type. The subsidiary's concurrent unit distribution of $0.49 per unit reinforces the capital return nature of the disclosure.
View raw filing on EDGAR →Kodiak Gas Services issued a press release on August 6, 2026, disclosing quarterly financial results for the period ended June 30, 2026, including net income of $52.0 million ($0.53 per diluted share), adjusted EBITDA of $216.8 million (21.7% increase YoY), and record discretionary cash flow of $163.3 million (40.2% increase YoY). The company also increased full-year 2026 guidance for adjusted EBITDA and discretionary cash flow. This is a standard earnings release disclosure under Item 2.02, furnished as Exhibit 99.1.
View raw filing on EDGAR →SpyGlass Pharma issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 net loss of $19.9 million (vs. $8.7 million in Q2 2025), R&D expenses of $10.9 million, G&A expenses of $11.0 million, and cash position of $234.2 million. The filing explicitly states this is furnished pursuant to Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for quarterly earnings releases.
View raw filing on EDGAR →WM Technology announced its Q2 2026 financial results on August 6, 2026, disclosing revenue of $42.4 million, net income of $2.9 million, and adjusted EBITDA of $5.0 million. The full press release is furnished as Exhibit 99.1 and includes consolidated balance sheets, forward-looking guidance for Q3 2026, and management commentary on operating performance. This is a standard quarterly earnings release under Item 2.02.
View raw filing on EDGAR →UWM entered into a securities purchase agreement on August 5, 2026, issuing 1.65 billion warrants (Class A and Class B) plus 1.5 million Series A-1 and 150,000 Series A-2 preferred shares for $1.65 billion in gross proceeds from Oaktree Capital Management and the Ishbia family. The transaction includes a rights offering to distribute up to 200 million shares of Class A Common Stock for at least $400 million in aggregate proceeds, fully backstopped by the Ishbia Purchaser.
View raw filing on EDGAR →UWM released Q2 2026 financial results (ended June 30, 2026) disclosing total revenue of $888.0 million, net loss of $451.9 million, adjusted EBITDA of $185.9 million, and loan origination volume of $39.7 billion, along with announcement of a dividend suspension.
View raw filing on EDGAR →Nicholas Basso was appointed as a director effective August 5, 2026, and to the Compensation Committee, pursuant to Oaktree Capital Management's contractual right to nominate directors under the Series A-1 Certificate of Designation and Investor Rights Agreement following the closing of the $2.05 billion equity financing.
View raw filing on EDGAR →Viatris issued a press release on August 6, 2026, reporting second-quarter 2026 financial results for the period ended June 30, 2026, including total revenues of $3.8 billion, adjusted EBITDA of $1.2 billion, adjusted EPS of $0.69, and raised full-year 2026 guidance.
View raw filing on EDGAR →The Item 2.02 disclosure announces Shift4 Payments' financial results for the quarter ended June 30, 2026, with the full press release furnished as Exhibit 99.1. This is a standard quarterly earnings announcement, which is a material event affecting investor assessment of the registrant's operational and financial performance.
View raw filing on EDGAR →MP Materials issued a press release on August 6, 2026 announcing financial results for the three months ended June 30, 2026, disclosing consolidated revenue of $108.5 million (89% increase YoY), Adjusted EBITDA of $28.5 million, and net loss of $(20.3) million. The filing includes full financial statements (balance sheet, income statement, cash flows) and segment results, which is the standard format for quarterly earnings disclosures under Item 2.02.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 (quarter ended June 27, 2026). The Item 2.02 disclosure explicitly states that the Company "issued a press release, furnished as Exhibit 99.1...announcing the Company's financial results for the quarter ended June 27, 2026." The exhibit contains consolidated statements of operations, balance sheets, and cash flows with detailed financial metrics including revenue ($507.4M), net income, EPS, and segment performance data. The filing also includes forward guidance for fiscal year 2026.
View raw filing on EDGAR →Rocket Companies issued a press release on August 6, 2026 announcing Q2 2026 financial results, including total revenue of $2.78 billion, GAAP net income of $229 million, and adjusted net income of $441 million.
View raw filing on EDGAR →Kevin D. Leary was appointed to the Board of Directors of American Outdoor Brands effective August 4, 2026, and assigned to the Compensation Committee and Nominations and Corporate Governance Committee. The appointment brings significant experience in investment management, capital allocation, and corporate governance to the board.
View raw filing on EDGAR →Unity Software Inc. disclosed its Q2 2026 financial results via press release on August 6, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). The disclosure includes comprehensive financial statements showing total revenue of $546 million (up 24% YoY), strategic revenue of $486 million (up 38% YoY), adjusted EBITDA of $160 million with 29% margin, and free cash flow of $202 million. The CEO characterized it as "arguably the best quarter in Unity's history as a public company." This is a standard quarterly earnings release with full financial tables and forward guidance, clearly material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →Nerdy Inc. committed on July 31, 2026 to wind down its Varsity Tutors for Schools business line, with estimated exit-related costs of $2–$4 million including $0.3–$0.5 million in employee severance and termination benefits, $0.5–$1.3 million in contract termination costs, and $1.4–$1.6 million in asset impairment charges. This is a material operational restructuring with workforce reduction and associated exit costs disclosed under Item 2.05, the standard Item for such events.
View raw filing on EDGAR →ESS Tech disclosed its cash position as of July 31, 2026, reporting $5.6 million in cash, cash equivalents, and short-term investments. This liquidity disclosure is material to investors assessing the company's financial health and ability to fund operations.
View raw filing on EDGAR →Tarsus Pharmaceuticals entered into a definitive Agreement and Plan of Merger on July 31, 2026, to acquire Alkeus Pharmaceuticals, a privately-held biotechnology company with a Phase 3 program for gildeuretinol (Stargardt disease), for approximately $450 million in upfront consideration ($270 million cash and $180 million in stock) plus up to $350 million in milestone payments and tiered royalties.
View raw filing on EDGAR →Tarsus Pharmaceuticals completed a private placement (PIPE) of approximately $125.0 million, consisting of 2,098,519 shares of common stock at $56.00 per share and pre-funded warrants to purchase 133,625 additional shares at $0.0001 per share. The unregistered securities were sold to qualified institutional buyers and accredited investors under Section 4(a)(2) of the Securities Act, with registration rights to be granted under a Registration Rights Agreement.
View raw filing on EDGAR →Tarsus Pharmaceuticals issued a press release on August 6, 2026, disclosing financial results for the second quarter and six months ended June 30, 2026. The filing explicitly states under Item 2.02 that the company "issued a press release, which, among other matters, sets forth the Company's results of operations for the three and six months ended June 30, 2026." The press release includes detailed quarterly and year-to-date financial metrics (product sales of $173.9M in Q2 2026 vs. $102.7M in Q2 2025, net loss of $18.6M vs. $20.3M, and updated full-year guidance of $685-705M), making this a standard earnings release disclosure.
View raw filing on EDGAR →Grindr issued a press release and shareholder letter on August 6, 2026, announcing financial results for Q2 2026 (quarter ended June 30, 2026). The disclosure includes Q2 revenue of $138 million (33% growth), net income of $18 million, and adjusted EBITDA of $58 million, along with raised full-year 2026 guidance. This is a standard earnings release disclosure under Item 2.02, with exhibits 99.1 and 99.2 containing the press release and shareholder letter respectively.
View raw filing on EDGAR →Sotera Health issued a press release on August 6, 2026, announcing financial results for the quarter ended June 30, 2026 (Q2 2026). The disclosure includes quarterly net revenues, net income, Adjusted EBITDA, Adjusted EPS, and segment-level performance metrics, along with an upward revision to full-year 2026 guidance. This is a standard earnings release attached as Exhibit 99.1 and disclosed under Item 2.02, which is the designated Item for results of operations and financial condition.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 financial results. The filing discloses quarterly revenue of $51.4 million, net loss of $(21.6) million, and Adjusted EBITDA of $8.7 million, along with updated full-year 2026 guidance raising Adjusted EBITDA guidance to $33–$35 million. The press release is furnished as Exhibit 99.1 and is the primary disclosure under Item 2.02, which is the standard Item for earnings announcements.
View raw filing on EDGAR →This is a clear earnings release disclosing Q2 2026 financial results for Playtika Holding Corp. The Item 2.02 section explicitly states "Playtika Holding Corp. issued a press release announcing its financial results for the quarter ended June 30, 2026," with the press release furnished as Exhibit 99.1. The exhibit contains comprehensive financial statements, revenue metrics ($731.1M), net income ($48.0M), Adjusted EBITDA ($206.1M), and forward guidance, all typical of a quarterly earnings announcement.
View raw filing on EDGAR →Micware Co., Ltd. is undergoing a multi-step absorption-type company split effective September 1, 2026, involving three separate reorganizations: (1) Micware Navigations Co., Ltd. will assume the location-based services business from Micware Co., Ltd.; (2) Micware Navigations Co., Ltd. and Micware Automotive Co., Ltd. will exchange business divisions with Navigations assuming Automotive's location-based services business and Automotive assuming Navigations' in-vehicle business; and (3) Micware Navigations Co., Ltd. and Micware Mobility Co., Ltd. will exchange business divisions with Navigations assuming Mobility's location-based services business and Mobility assuming Navigations' in-vehicle business. These material reorganizations constitute a significant change of control and restructuring of the registrant's business segments.
View raw filing on EDGAR →The filing discloses entry into a definitive merger agreement on August 5, 2026, whereby Sunrise Realty Trust, Inc. will acquire Southern Realty Trust Inc. through a merger. The transaction involves an exchange ratio of 1.45 shares of SUNS common stock per SRT share plus $0.05 cash per share, with SUNS expected to issue approximately 8.4 million shares. This is a material acquisition consolidating two CRE lending platforms into a single public company, subject to stockholder approval and expected to close in Q4 2026.
View raw filing on EDGAR →Robert You resigned as President and Chief Financial Officer effective July 31, 2026, with no disagreement cited. While the filing also discloses Vikas Mittal's appointment as Interim CFO, the primary disclosed action centers on You's departure from a named executive officer role. The appointment is secondary and interim in nature, making the departure the more salient event.
View raw filing on EDGAR →PureCycle Technologies disclosed its second quarter 2026 financial results via press release, reporting revenue of $4.5 million (up 173% year-over-year), net loss of $142.2 million, operating loss of $41.3 million, and adjusted EBITDA of $(31.7) million, along with operational highlights including first P&G commercial resin deliveries and facility approvals.
View raw filing on EDGAR →Serve Robotics announced Q2 2026 financial results on August 6, 2026, reporting revenue of $3.2 million (404% YoY growth), a net loss of $64.1 million, and revised full-year 2026 guidance of $9–10 million in revenue. The announcement included condensed consolidated financial statements, key metrics, and management commentary on business performance and outlook.
View raw filing on EDGAR →This is a quarterly earnings press release disclosing Q2 2026 financial results for Cresco Labs Inc., including revenue of $173 million, net income of $15 million, and Adjusted EBITDA of $40 million. The document explicitly states "Cresco Labs Reports Second Quarter 2026 Financial Results" and includes consolidated financial statements, cash flow data, and non-GAAP reconciliations typical of an earnings announcement. While the exhibit also mentions a CFO departure (Sharon Schuler stepping down), the primary and dominant disclosure is the quarterly financial results, making this an earnings_release event.
View raw filing on EDGAR →The Trust declared a monthly cash distribution of $0.086363 per certificate (totaling $6,477,192.79) to be paid on August 10, 2026 to certificateholders of record as of August 7, 2026, as disclosed in the monthly report for July 2026.
View raw filing on EDGAR →Grove Collaborative issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing net revenue of $36.6 million (down 16.9% YoY), net loss of $0.9 million, and positive adjusted EBITDA of $0.5 million (third consecutive quarter positive), while reaffirming full-year 2026 guidance.
View raw filing on EDGAR →OmniAb issued a press release on August 6, 2026 announcing financial results for the three and six months ended June 30, 2026, including revenue of $13.4 million (Q2) and $27.8 million (H1), net loss of $5.9 million (Q2) and $13.6 million (H1), and updated 2026 full-year revenue guidance to $32–$36 million (raised from $28–$33 million). The disclosure includes detailed operating metrics, expense breakdowns, and cash position, furnished as Exhibit 99.1 per Item 2.02.
View raw filing on EDGAR →Blend Labs announced Q2 2026 financial results with revenue of $33.8 million (up 7% YoY) and non-GAAP operating income of $7.0 million, along with Q3 2026 forward guidance. The earnings press release was posted to the company's website and furnished to investors via Items 2.02 and 7.01.
View raw filing on EDGAR →This is a clear earnings release disclosing Krispy Kreme's Q2 2026 financial results (ended June 28, 2026) issued on August 6, 2026. The press release reports net revenue of $331.0 million, GAAP net loss of $19.8 million, Adjusted EBITDA of $28.8 million, and other key financial metrics, along with segment results and forward guidance. The filing is structured as Item 2.02 with the press release attached as Exhibit 99.1, which is the standard format for earnings disclosures.
View raw filing on EDGAR →GigaCloud issued a press release on August 6, 2026 announcing financial results for Q2 and six months ended June 30, 2026, reporting record second quarter revenue of $411.6 million (up 27.6% year-over-year) and diluted EPS of $1.16 (up 27.5% year-over-year).
View raw filing on EDGAR →The Board approved on August 5, 2026 a new $120.0 million share repurchase program effective August 6, 2026, replacing the prior 2025 Program, representing a material capital allocation decision to return capital to shareholders.
View raw filing on EDGAR →The filing discloses unaudited financial results for Q2 2026 via a press release (Exhibit 99.1), including revenues of $91.4 million (up 4.1% YoY), net income of $27.4 million (up 31.7% YoY), and diluted EPS of $1.43 (up 33.6% YoY). The company also reaffirmed full-year 2026 guidance and released Q3 2026 guidance. This is a standard quarterly earnings release disclosure under Item 2.02.
View raw filing on EDGAR →Xeris Biopharma issued a press release on August 6, 2026, disclosing financial results for the second quarter and six months ended June 30, 2026. The filing explicitly states in Item 2.02 that the Company "issued a press release containing information about the Company's results of operations and business highlights" and furnishes the press release as Exhibit 99.1. The exhibit contains detailed quarterly and year-to-date financial results including revenue ($92.1M Q2, $175.2M YTD), product-specific revenue breakdowns, gross margin, operating expenses, net loss, and Adjusted EBITDA, along with forward-looking guidance tightening full-year 2026 revenue to $385–$390 million. This is a standard earnings release disclosure under Item 2.02.
View raw filing on EDGAR →Constellation Energy announced Q2 2026 financial results with GAAP Net Income of $1.42 per share and Adjusted Operating Earnings of $2.55 per share, along with raised full-year guidance to $11.50–$12.50 per share.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 results. The Item 2.02 disclosure explicitly states that Orion Properties furnished "a press release relating to its second quarter 2026 results" (Exhibit 99.1), which contains detailed financial results including revenues of $34.3 million, net income of $24.6 million, FFO of $0.16 per diluted share, and Core FFO of $0.20 per diluted share, along with updated 2026 guidance. This is a material disclosure affecting investor assessment of the registrant's financial performance.
View raw filing on EDGAR →Arhaus disclosed second quarter 2026 financial results via press release, reporting net revenue of $385 million (up 7.4% YoY), net income of $40 million (up 13.1% YoY), and adjusted EBITDA of $70 million (up 16.8% YoY), along with updated full-year 2026 guidance.
View raw filing on EDGAR →ESAB issued a press release on August 6, 2026 reporting second quarter 2026 financial results, including record sales of $808 million (up 12.9%), net income from continuing operations of $35 million ($0.54 diluted EPS), and core adjusted EBITDA of $150 million. The company also updated its full-year 2026 outlook, raising core sales growth guidance to 11.0%-14.0% and core adjusted EBITDA forecast to $615-625 million. This is a standard quarterly earnings disclosure with material financial metrics and forward guidance.
View raw filing on EDGAR →